Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous Dendritic Cell HIV Vaccination (NIAID)
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
Autologous Dendritic Cell HIV Vaccination is an experimental cellular immunotherapy developed by the National Institute of Allergy and Infectious Diseases (NIAID) for the treatment of HIV-1 infection. The therapy involves the ex vivo differentiation of a patient's own adherent monocytic precursors into mature dendritic cells, which are then pulsed with a cocktail of highly conserved HIV-1 derived peptides and an influenza matrix peptide. These antigen-presenting cells are re-introduced into the patient via intravenous or subcutaneous injection to prime and expand HIV-specific CD8+ and CD4+ T-cell populations. By targeting highly conserved regions of the HIV-1 genome, the vaccine aims to overcome viral mutational escape and enhance the immune system's ability to control viral load in individuals on highly active antiretroviral therapy (HAART).
- Other names
- Autologous Dendritic Cell HIV-1 VaccineHIV-1 Peptide-Pulsed Autologous Dendritic Cell VaccineHIV1 Peptide-Pulsed Autologous Dendritic Cell VaccineHIV 1 Peptide-Pulsed Autologous Dendritic Cell Vaccine
Beyond the preview
Go deeper on Autologous Dendritic Cell HIV Vaccination (NIAID).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous Dendritic Cell HIV Vaccination (NIAID).